Arca
Skip to content
Tools
Tools

SCN9A: Sodium channel protein type 9 subunit alpha

Pore-forming subunit of Nav1.7, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes.

  • Drugs that act on it: 7
  • Approved: 0
  • In phases 1 to 3: 7
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on SCN9A, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 3
  • Other 4

Approved0

    Phase 31

    • Vixotrigine

    Phase 21

    • PF-05089771

    Phase 15

    • AZD3161
    • DSP-2230
    • RG6029
    • RG7893
    • XEN403

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Sodium channel protein type IX alpha subunit blocker.
    VixotriginePhase 3BiogenSmall moleculeBlocker0
    PF-05089771Phase 2PfizerSmall moleculeBlocker0
    AZD3161Phase 1AstraZeneca PharmaceuticalsOtherBlocker0
    DSP-2230Phase 1—Small moleculeBlocker0
    RG6029Phase 1—OtherBlocker0
    RG7893Phase 1—OtherBlocker0
    XEN403Phase 1—OtherBlocker0

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Primary erythermalgia0.82
    • Paroxysmal extreme pain disorder0.79
    • Channelopathy-associated congenital insensitivity to pain, autosomal recessive0.74
    • Hereditary sensory and autonomic neuropathy type 20.66
    • Seizure0.64
    • Pain0.61
    • Focal epilepsy0.59

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4296, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt Q15858, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.